Tvardi Therapeutics (NASDAQ:TVRD) Stock Rating Lowered by Wall Street Zen

Tvardi Therapeutics (NASDAQ:TVRD) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Monday.

Several other analysts have also recently commented on TVRD. Cantor Fitzgerald lowered shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 13th. Piper Sandler lowered shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 13th. Weiss Ratings reiterated a “sell (e)” rating on shares of Tvardi Therapeutics in a research note on Monday, December 22nd. Raymond James Financial cut Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, October 14th. Finally, BTIG Research cut their target price on Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating for the company in a research report on Monday, October 13th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $55.50.

Tvardi Therapeutics Price Performance

NASDAQ:TVRD opened at $4.14 on Monday. Tvardi Therapeutics has a 12 month low of $3.74 and a 12 month high of $43.65. The business’s 50-day moving average is $4.30 and its two-hundred day moving average is $19.54. The firm has a market capitalization of $38.83 million, a PE ratio of -0.43 and a beta of 0.11.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.24. Tvardi Therapeutics had a negative return on equity of 282.16% and a negative net margin of 585.37%.

Institutional Investors Weigh In On Tvardi Therapeutics

Institutional investors have recently made changes to their positions in the company. Vestal Point Capital LP bought a new stake in Tvardi Therapeutics during the third quarter valued at about $6,508,000. Parkman Healthcare Partners LLC acquired a new position in shares of Tvardi Therapeutics during the 3rd quarter worth about $2,533,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Tvardi Therapeutics during the 3rd quarter worth about $746,000. Squarepoint Ops LLC bought a new stake in Tvardi Therapeutics during the 3rd quarter valued at approximately $318,000. Finally, Invesco Ltd. acquired a new stake in Tvardi Therapeutics in the 3rd quarter valued at approximately $3,219,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.